Anti-tumour necrosis factor treatment increases circulating T helper type 17 cells similarly in different types of inflammatory arthritis. [electronic resource]
Producer: 20151117Description: 401-6 p. digitalISSN:- 1365-2249
- Adalimumab
- Adult
- Aged
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antirheumatic Agents -- therapeutic use
- Arthritis, Psoriatic -- blood
- Arthritis, Rheumatoid -- blood
- Enzyme-Linked Immunosorbent Assay
- Etanercept
- Female
- Flow Cytometry
- Humans
- Immunoglobulin G -- therapeutic use
- Interleukin-17 -- blood
- Male
- Middle Aged
- Prospective Studies
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Spondylitis, Ankylosing -- blood
- Th17 Cells -- drug effects
- Time Factors
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Observational Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.